Peptide Pandemonium: A Wild West of Unregulated Medicine The FDA's upcoming panel meeting on peptide production has sparked a frenzy among compounding pharmacies, telehealth giants, and longevity enthusiasts.
The gathering in Maryland marks more than just a discussion about the safety and efficacy of these injectable amino acid based drugs – it's a fight for control over a potentially lucrative market.
The FDA's technical staff have recommended against expanded access to these peptides, citing concerns about contamination, incorrect dosing, and other problems associated with the existing gray market.